Representatives of the pharmaceutical, biotechnology and generic drugs industries spent a couple of days this week at the US Food and Drug Administration headquarters in Rockville, Maryland, to discuss the implementation and regulation of a regulatory pathway for follow-on biologics - or biosimilars - medications.
On March 23, 2010, President Barack Obama signed into law the Patient Protection and Affordable Care Act which contained a provision authorizing the FDA to create an abbreviated approval pathway for biological products shown to be biosimilar to with an already FDA-approved biological medicine. Several countries have already implemented approval pathways for biosimilars. The European Union and Japan are among those that have successfully devised a set of science-based criteria to permit biosimilars in their jurisdictions. With the FDA's hearing on November 2-3, the USA is beginning the implementation process, but a quick resolution is not expected.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze